Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
$26.35
$26.35
$8.10
$26.73
$1.00B0.64145,059 shs716,706 shs
Merus stock logo
MRUS
Merus
$54.27
-2.0%
$46.03
$33.19
$62.98
$3.76B1.04749,285 shs396,180 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.85
-1.5%
$25.98
$23.14
$30.93
$3.69B0.461.53 million shs380,496 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$35.94
-3.7%
$46.51
$34.10
$173.25
$3.53B0.611.80 million shs1.83 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Merus stock logo
MRUS
Merus
+0.62%-1.11%+35.36%+17.60%-2.24%
Perrigo Company plc stock logo
PRGO
Perrigo
-0.69%+4.80%+3.73%-0.15%-2.23%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-1.32%-4.85%+3.07%-61.61%-68.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Merus stock logo
MRUS
Merus
3.0924 of 5 stars
4.63.00.00.02.11.70.0
Perrigo Company plc stock logo
PRGO
Perrigo
4.5537 of 5 stars
2.13.04.23.52.31.72.5
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.7609 of 5 stars
4.42.00.04.23.11.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
0.00
N/AN/AN/A
Merus stock logo
MRUS
Merus
3.13
Buy$85.8358.16% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0022.91% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.87
Moderate Buy$122.61241.20% Upside

Current Analyst Ratings Breakdown

Latest CMTA, MRUS, SRPT, and PRGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$80.00
5/23/2025
Merus stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/22/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$40.00 ➝ $40.00
5/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$169.00 ➝ $84.00
5/19/2025
Merus stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/8/2025
Merus stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/8/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$188.00 ➝ $85.00
5/8/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$115.00 ➝ $100.00
5/8/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Inline$50.00
5/7/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$87.00 ➝ $58.00
5/7/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$178.00 ➝ $100.00
(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/AN/AN/AN/A$5.18 per shareN/A
Merus stock logo
MRUS
Merus
$54.73M68.63N/AN/A$6.17 per share8.80
Perrigo Company plc stock logo
PRGO
Perrigo
$4.34B0.85$5.61 per share4.79$35.19 per share0.76
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.23B1.58N/AN/A$9.19 per share3.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
-$58.13M-$7.93N/AN/AN/AN/A-44.73%-41.66%N/A
Merus stock logo
MRUS
Merus
-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$12.70M-$1.31N/A8.77N/A-3.64%7.38%3.18%8/1/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$535.98M-$2.6928.703.28N/A7.43%11.00%3.35%8/6/2025 (Estimated)

Latest CMTA, MRUS, SRPT, and PRGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Merus stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
5/6/2025Q1 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/AN/AN/AN/AN/A
Merus stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.32%N/AN/A 23 Years
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A

Latest CMTA, MRUS, SRPT, and PRGO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/A
14.03
14.03
Merus stock logo
MRUS
Merus
N/A
8.32
8.32
Perrigo Company plc stock logo
PRGO
Perrigo
0.94
2.56
1.77
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.93
3.84
3.03

Institutional Ownership

CompanyInstitutional Ownership
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
78.72%
Merus stock logo
MRUS
Merus
96.14%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/A
Merus stock logo
MRUS
Merus
4.57%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
3038.06 millionN/ANot Optionable
Merus stock logo
MRUS
Merus
3769.21 million65.34 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,900137.48 million135.47 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
84098.28 million88.17 millionOptionable

Recent News About These Companies

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clementia Pharmaceuticals stock logo

Clementia Pharmaceuticals NASDAQ:CMTA

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Merus stock logo

Merus NASDAQ:MRUS

$54.27 -1.12 (-2.02%)
As of 02:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.85 -0.40 (-1.47%)
As of 02:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$35.94 -1.38 (-3.69%)
As of 02:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.